Skip to main content
. Author manuscript; available in PMC: 2021 Jul 21.
Published in final edited form as: N Engl J Med. 2020 Dec 5;384(3):205–215. doi: 10.1056/NEJMoa2029392

Table 4.

Clinical Events before and after Infusion.*

Patient Number Months since Infusion No. of Transfusions (Annualized) No. of Severe Sickle Cell Clinical Events
Prestudy After Engraftment Prestudy After Gene Therapy (<5 mo) After Gene Therapy (≥5 mo)
2 29 12.5 0 0 0 0
3 19 10.5 5.7 0 0 0
4 20 2 0 13 5 1
6 16 3 0 6 0 0
7 12 11 0 0 0 0
8 7 1 0 3 0 0
*

Prestudy events represent the 2 years preceding study enrollment. Events that occurred after gene therapy represent the time from engraftment to the most recent follow-up.

Events include vaso-occlusive crisis pain requiring an emergency department visit or admission for opioid treatment, admission for acute chest syndrome, and priapism events requiring an emergency department visit or admission for a procedural intervention.

The most recent severe event was an emergency department visit that occurred 8 months after gene therapy.